Practical aspects of in vivo antimalarial drug efficacy testing in the Americas.
Am J Trop Med Hyg
; 68(4): 391-7, 2003 Apr.
Article
en En
| MEDLINE
| ID: mdl-12875285
ABSTRACT
The World Health Organization (WHO) has developed guidelines for in vivo antimalarial drug efficacy testing for Plasmodium falciparum and Plasmodium vivax in areas with low-to-moderate transmission, such as the Americas. These guidelines are used widely by ministries of health and national malaria control programs to assess the efficacy of their first-line and second-line drugs for the treatment of malaria and to provide the information necessary to update national malaria treatment policies. Following the WHO guidelines, we have conducted in vivo efficacy trials with a variety of drugs and drug combinations against P. falciparum and P. vivax at 13 sites in Peru, Bolivia, and Ecuador. Based on these experiences, we have identified several modifications that we believe should be made in the WHO recommendations to make them more suitable to the relatively low levels of P. falciparum transmission in the Americas and to the logistic challenges of carrying out such studies in sparsely populated areas, such as the Amazon Basin. These include changes in inclusion and exclusion criteria, in enrollment and follow-up procedures, and in the measurement of study outcomes.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Malaria Vivax
/
Malaria Falciparum
/
Guías como Asunto
/
Antimaláricos
Tipo de estudio:
Guideline
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Animals
/
Female
/
Humans
/
Pregnancy
País/Región como asunto:
America do sul
/
Bolivia
/
Ecuador
/
Peru
Idioma:
En
Revista:
Am J Trop Med Hyg
Año:
2003
Tipo del documento:
Article
País de afiliación:
Perú